Long‐term efficacy and safety results from an open‐label phase III study (UNCOVER‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab

Podobne knjige/članki

• Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study (UNCOVER‐J)
  od: Okubo, Y., et al.
  Izdano: (2018)
• Efficacy and safety of ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis: Subgroup analysis of a placebo‐controlled, phase 3 study (UNCOVER‐1)
  od: Imafuku, Shinichi, et al.
  Izdano: (2017)
• Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J)
  od: Saeki, Hidehisa, et al.
  Izdano: (2016)
• Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
  od: Honma, Masaru, et al.
  Izdano: (2020)
• Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
  od: Kazemi T, et al.
  Izdano: (2017-04-01)